Advanced non-small cell lung carcinoma (NSCLC) remains a challenge to treat due to its high local and systemic recurrence. The overall survival remains poor despite the approval of several new chemotherapeutic agents in the management of advanced NSCLC. Overexpression or mutations in the EGFR have been shown to be associated with a significant percentage of NSCLC. The development of targeted agents, such as cetuximab, against the EGFR is therefore a rational objective. Several preclinical and clinical studies suggest that cetuximab is active against NSCLC. This paper reviews the application of cetuximab in NSCLC.
Cetuximab in non-small cell lung cancer. Publishing Authors By Initials
Cetuximab in non-small cell lung cancer. Journal Published:
PUBLICATION TYPE: Journal Article
Journal: Expert opinion on biological therapy
VOLUME: 8
Page Numbers: 107-13
Journal Abbreviation:
ISSN: 1744-7682
DAY: 17
MONTH: Jan
YEAR: 2008
Cetuximab in non-small cell lung cancer. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 101125414
Cetuximab in non-small cell lung cancer. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Cetuximab in non-small cell lung cancer. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Cetuximab in non-small cell lung cancer.
AFFILIATION: Indiana University School of Medicine, Division of Hematology/Oncology, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA +1 317 278 6942 ; +1 317 278 4910 ; fademuyi@iupui.edu.
Country: England
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Expert Opin Biol Ther
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Cetuximab in non-small cell lung cancer Related Publications